Translating Science, Transforming Lives
When Stu Peltz founded PTC more than 20 years ago, he did it with a clear vision of what he wanted to create: a patient-centric approach to treating rare disease. During that time, the company has grown an enormous amount, expanding its reach from its office in New Jersey to countries around the world. That growth was made possible by achieving a number of milestones throughout the years.
PTC is a US pharmaceutical company focused on the development of orally administered small molecule drugs that regulate gene expression by targeting Post-Translational Control (PTC) mechanisms in orphan diseases. The company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs which are used for the treatment of Genetic Disorders, Oncology, and Infectious Diseases like metastatic breast cancer, multiple tumors, Duchenne muscular dystrophy, and neurofibromatosis.